Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11

1.

Targeting the STAT5 pathway in Ph+ acute lymphoblastic leukemia.

Minieri V, De Dominici M, Nevalainen MT, Calabretta B.

Oncotarget. 2018 Dec 4;9(95):36726-36727. doi: 10.18632/oncotarget.26412. eCollection 2018 Dec 4. No abstract available.

2.

Semaphorin 5A drives melanoma progression: role of Bcl-2, miR-204 and c-Myb.

D'Aguanno S, Valentini E, Tupone MG, Desideri M, Di Martile M, Spagnuolo M, Buglioni S, Ercolani C, Falcone I, De Dominici M, Milella M, Rizzo MG, Calabretta B, Cota C, Anichini A, Trisciuoglio D, Del Bufalo D.

J Exp Clin Cancer Res. 2018 Nov 19;37(1):278. doi: 10.1186/s13046-018-0933-x.

3.

Targeting STAT5 or STAT5-Regulated Pathways Suppresses Leukemogenesis of Ph+ Acute Lymphoblastic Leukemia.

Minieri V, De Dominici M, Porazzi P, Mariani SA, Spinelli O, Rambaldi A, Peterson LF, Porcu P, Nevalainen MT, Calabretta B.

Cancer Res. 2018 Oct 15;78(20):5793-5807. doi: 10.1158/0008-5472.CAN-18-0195. Epub 2018 Aug 28.

PMID:
30154155
4.

Transcriptional activation of the miR-17-92 cluster is involved in the growth-promoting effects of MYB in human Ph-positive leukemia cells.

Spagnuolo M, Regazzo G, De Dominici M, Sacconi A, Pelosi A, Korita E, Marchesi F, Pisani F, Magenta A, Lulli V, Cordone I, Mengarelli A, Strano S, Blandino G, Rizzo MG, Calabretta B.

Haematologica. 2019 Jan;104(1):82-92. doi: 10.3324/haematol.2018.191213. Epub 2018 Aug 3.

5.

Targeting CDK6 and BCL2 Exploits the "MYB Addiction" of Ph+ Acute Lymphoblastic Leukemia.

De Dominici M, Porazzi P, Soliera AR, Mariani SA, Addya S, Fortina P, Peterson LF, Spinelli O, Rambaldi A, Martinelli G, Ferrari A, Iacobucci I, Calabretta B.

Cancer Res. 2018 Feb 15;78(4):1097-1109. doi: 10.1158/0008-5472.CAN-17-2644. Epub 2017 Dec 12.

PMID:
29233926
6.

Structure of Nascent Chromatin Is Essential for Hematopoietic Lineage Specification.

Petruk S, Mariani SA, De Dominici M, Porazzi P, Minieri V, Cai J, Iacovitti L, Flomenberg N, Calabretta B, Mazo A.

Cell Rep. 2017 Apr 11;19(2):295-306. doi: 10.1016/j.celrep.2017.03.035.

7.

Celecoxib inhibits proliferation and survival of chronic myelogeous leukemia (CML) cells via AMPK-dependent regulation of β-catenin and mTORC1/2.

Riva B, De Dominici M, Gnemmi I, Mariani SA, Minassi A, Minieri V, Salomoni P, Canonico PL, Genazzani AA, Calabretta B, Condorelli F.

Oncotarget. 2016 Dec 6;7(49):81555-81570. doi: 10.18632/oncotarget.13146.

8.

CDKN2A-independent role of BMI1 in promoting growth and survival of Ph+ acute lymphoblastic leukemia.

Mariani SA, Minieri V, De Dominici M, Iacobucci I, Peterson LF, Calabretta B.

Leukemia. 2016 Aug;30(8):1682-90. doi: 10.1038/leu.2016.70. Epub 2016 Apr 5.

9.

Structure-Based Screen Identifies a Potent Small Molecule Inhibitor of Stat5a/b with Therapeutic Potential for Prostate Cancer and Chronic Myeloid Leukemia.

Liao Z, Gu L, Vergalli J, Mariani SA, De Dominici M, Lokareddy RK, Dagvadorj A, Purushottamachar P, McCue PA, Trabulsi E, Lallas CD, Gupta S, Ellsworth E, Blackmon S, Ertel A, Fortina P, Leiby B, Xia G, Rui H, Hoang DT, Gomella LG, Cingolani G, Njar V, Pattabiraman N, Calabretta B, Nevalainen MT.

Mol Cancer Ther. 2015 Aug;14(8):1777-93. doi: 10.1158/1535-7163.MCT-14-0883. Epub 2015 May 29.

10.

c-Myb and its target Bmi1 are required for p190BCR/ABL leukemogenesis in mouse and human cells.

Waldron T, De Dominici M, Soliera AR, Audia A, Iacobucci I, Lonetti A, Martinelli G, Zhang Y, Martinez R, Hyslop T, Bender TP, Calabretta B.

Leukemia. 2012 Apr;26(4):644-53. doi: 10.1038/leu.2011.264. Epub 2011 Sep 30.

11.

[Preliminary data on geohelminthiasis in school children in Mede].

De Carneri I, De Dominici M, De Carneri A.

G Mal Infett Parassit. 1969 Nov;21(11):854-62. Italian. No abstract available.

PMID:
5397339

Supplemental Content

Loading ...
Support Center